{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(8)"],"submitter":["Doggrell SA"],"pubmed_abstract":["<h4>Introduction</h4>Lopinavir in combination with ritonavir is approved for the treatment of HIV and has recently been subject to a clinical trial in severe COVID-19.<h4>Areas covered</h4>This evaluation is of LOTUS China (the Lopinavir Trial for Suppression of SARS-Cov-2 in China), which was a randomized trial in hospitalized subjects with COVID-9 in a respiratory sample and pneumonia. As, in severe COVID-19, lopinavir/ritonavir had no beneficial effects but increased gastrointestinal adverse effects, this combination should not be used at this stage of COVID-19.<h4>Expert opinion</h4>In my opinion, the rationale for undertaking a trial of lopinavir/ritonavir in COVID-19 was poor. The analysis of a modified intention to treat group analysis in LOTUS China may have introduced bias. After "],"journal":["Expert opinion on investigational drugs"],"pagination":["793-796"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7441752"],"repository":["biostudies-literature"],"pubmed_title":["Does lopinavir measure up in the treatment of COVID-19?"],"pmcid":["PMC7441752"],"pubmed_authors":["Doggrell SA"],"additional_accession":[]},"is_claimable":false,"name":"Does lopinavir measure up in the treatment of COVID-19?","description":"<h4>Introduction</h4>Lopinavir in combination with ritonavir is approved for the treatment of HIV and has recently been subject to a clinical trial in severe COVID-19.<h4>Areas covered</h4>This evaluation is of LOTUS China (the Lopinavir Trial for Suppression of SARS-Cov-2 in China), which was a randomized trial in hospitalized subjects with COVID-9 in a respiratory sample and pneumonia. As, in severe COVID-19, lopinavir/ritonavir had no beneficial effects but increased gastrointestinal adverse effects, this combination should not be used at this stage of COVID-19.<h4>Expert opinion</h4>In my opinion, the rationale for undertaking a trial of lopinavir/ritonavir in COVID-19 was poor. The analysis of a modified intention to treat group analysis in LOTUS China may have introduced bias. After ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-18T20:42:55.618Z","creation":"2020-09-14T07:16:41Z"},"accession":"S-EPMC7441752","cross_references":{"pubmed":["32475183"],"doi":["10.1080/13543784.2020.1777277"]}}